CURRICULUM VITAE

Kelley W. Yokum, MD
Olympian Clinical Research
4238 W. Kennedy Blvd.
Tampa, FL 33609
KYokum@olympianresearch.com

EDUCATION:

University of South Florida, Tampa, FL
Child and Adolescent Psychiatry Fellow, 2009 –2010

University of South Florida, Tampa, FL
Psychiatry Resident, 2006-2009

University of Alabama School of Medicine, Birmingham, AL
Doctor of Medicine, June 2005

University of Alabama, Huntsville, AL
Bachelors of Science in Biology, Dec 1999

WORK EXPEREINCE:

JUL 2012- Present	Olympian Clinical Research Sub Investigator	Tampa, FL
NOV 2010- NOV 2011	Veterans Administration Psychiatrist	Lakeland, FL
DEC 1999- JUN 2001	Battelle Memorial Institute Researcher	Huntsville, AL

BOARD CERTIFICATION:

2011 American Board of Psychiatry and Neurology

LICENSURE:

2009 Florida, ME 105565 (active)

CLINICAL RESEARCH EXPERIENCE:

2010 Murphy, T., & Yokum, K. (2011). Immune and Endocrine Function in Child and Adolescent Obsessive Compulsive Disorder. In E. A. Storch, & D. McKay. *Handbook of Child and Adolescent Anxiety Disorders*. (pp. 505-520). New York. Springer Science + Business Media.

2002 CaRES Intern and Research Assistant, University of Alabama at Birmingham, Department of Dermatology working with Laura Timares, PhD. – Participated in research of Langerhan cell migration and transgene expression following genetic immunization.

A Phase 3, Multi-Site, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of The Efficacy And Safety Of 2 Oral Doses Of XXX In Subjects With Moderate To Severe Chronic Plaque Psoriasis (Pfizer).

A Phase 3, Multi Site, Open- Label study Of the Long Term Safety and Tolerability of 2 Oral doses of XXX drug in subjects with Moderate to Severe Chronic Plaque Psoriasis (Pfizer).

A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject –Tailored" Maintenance Dosing approach in Subjects with Moderate to Severe Psoriasis (Janssen).

A Multiple-Dose, Randomized, Blinded, Vehicle- and Active Comparator- Controlled Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical XXX Ointment, Applied Twice Daily for 28 days, in Adult Subjects With Atopic Dermatitis (Otsuka).

Open Label Study to Evaluate the Efficacy of XXX Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to XXX (Amgen).

APPLES: A prospective pediatric longitudinal evaluation to assess the long-term safety of XXX ointment for the treatment of atopic dermatitis (Astellas).

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of XXX capsules in Adult Subjects with Atopic Dermatitis (Asubio).

A multicenter, open registry of patients with Psoriasis who are candidates for systemic therapy including biologics (Centocor).

A 64-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous XXX, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Merck).

A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of XXX Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis (Stiefel).

A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of XXX Foam, 0.005% Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) with Plaque Psoriasis (Stiefel).

A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing XXX Topical Gel (Taro Pharmaceuticals, Inc.) to XXX Topical Gel (Sanofi Aventis) in the Treatment of Acne Vulgaris (Taro).

Kelley Yokum 28NOV2012
Kelley Yokum, MD
Updated 11/28/2012